testosterone undecanoate
(UDSFVOAUHKGBEK-CNQKSJKFSA-N)
Structure
- SMILES
- CCCCCCCCCCC(=O)O[C@H]1CC[C@@H]2[C@]1(C)CC[C@H]1[C@H]2CCC2=CC(=O)CC[C@]12C
- Type(s)
- Approved; Investigational
- Molecular Formula:
- C30H48O3
- Molecular Weight:
- 456.700
- Log P:
- 7.9609
- Hydrogen Bond Acceptor:
- 3
- Hydrogen Bond Donor:
- 0
- TPSA:
- 43.37
- CAS Number(s):
- 5949-44-0
Synonym(s)
1.
testosterone undecanoate
2.
Andriol
3.
Nebido
4.
Pantestone
5.
Restandol
6.
Undestor
7.
testosterone undecylate
External Link(s)
Adverse Drug Event(s)
| Name | Number of Reports | Reference(s) | Data Source | |
|---|---|---|---|---|
| 1 | Drug ineffective | FAERS: 222 Canada Vigilance: 2 | Canada Vigilance US FAERS | |
| 2 | Pulmonary oil microembolism | FAERS: 51 | US FAERS | |
| 3 | Blood testosterone decreased | FAERS: 42 Canada Vigilance: 1 | Canada Vigilance US FAERS | |
| 4 | Inappropriate schedule of drug administration | FAERS: 36 | US FAERS | |
| 5 | Injection site pain | FAERS: 34 | US FAERS | |
| 6 | Fatigue | FAERS: 30 | US FAERS | |
| 7 | Dizziness | FAERS: 20 | US FAERS | |
| 8 | Asthenia | FAERS: 19 | US FAERS | |
| 9 | Chest Pain | FAERS: 13 | US FAERS | |
| 10 | Malaise | FAERS: 13 | US FAERS | |
| 11 | Hypersensitivity | FAERS: 11 | US FAERS | |
| 12 | Microembolism | FAERS: 11 | US FAERS | |
| 13 | Erythema | FAERS: 10 | US FAERS | |
| 14 | Feeling abnormal | FAERS: 9 | US FAERS | |
| 15 | Flushing | FAERS: 9 | US FAERS | |
| 16 | Pulmonary microemboli | FAERS: 9 | US FAERS | |
| 17 | Acne | FAERS: 8 | US FAERS | |
| 18 | Chest discomfort | FAERS: 8 | US FAERS | |
| 19 | Mood swings | FAERS: 8 | US FAERS | |
| 20 | Incorrect drug administration rate | FAERS: 7 | US FAERS | |
| 21 | Product quality issue | FAERS: 7 | US FAERS | |
| 22 | Wrong technique in product usage process | FAERS: 7 | US FAERS | |
| 23 | Headache | FAERS: 6 | US FAERS | |
| 24 | Incorrect route of drug administration | FAERS: 6 | US FAERS | |
| 25 | Injection site erythema | FAERS: 6 | US FAERS | |
| 26 | Peripheral swelling | FAERS: 6 | US FAERS | |
| 27 | Pruritus | FAERS: 6 | US FAERS | |
| 28 | Syncope | FAERS: 6 | US FAERS | |
| 29 | Chills | FAERS: 5 | US FAERS | |
| 30 | Deep Vein Thrombosis | FAERS: 5 | US FAERS | |
| 31 | Inappropriate schedule of product administration | FAERS: 5 | US FAERS | |
| 32 | Palpitations | FAERS: 5 | US FAERS | |
| 33 | Sluggishness | FAERS: 5 | US FAERS | |
| 34 | Somnolence | FAERS: 5 | US FAERS | |
| 35 | Unevaluable event | FAERS: 5 | US FAERS | |
| 36 | Alopecia | FAERS: 4 | US FAERS | |
| 37 | Anxiety | FAERS: 4 | US FAERS | |
| 38 | Arthralgia | FAERS: 4 | US FAERS | |
| 39 | Blood testosterone increased | FAERS: 4 | US FAERS | |
| 40 | Burning sensation | FAERS: 4 | US FAERS | |
| 41 | Cold sweat | FAERS: 4 | US FAERS | |
| 42 | Depressed mood | FAERS: 4 | US FAERS | |
| 43 | Dysgeusia | FAERS: 4 | US FAERS | |
| 44 | Erectile dysfunction | FAERS: 4 | 20345732 | CTD US FAERS |
| 45 | Nausea | FAERS: 4 | US FAERS | |
| 46 | Pallor | FAERS: 4 | US FAERS | |
| 47 | Throat irritation | FAERS: 4 | US FAERS | |
| 48 | Weight decreased | FAERS: 4 Canada Vigilance: 2 | Canada Vigilance US FAERS | |
| 49 | Agitation | FAERS: 3 | US FAERS | |
| 50 | Blood pressure fluctuation | FAERS: 3 | US FAERS | |
| 51 | Bronchospasm | FAERS: 3 | US FAERS | |
| 52 | Constipation | FAERS: 3 | US FAERS | |
| 53 | Drug dose omission | FAERS: 3 | US FAERS | |
| 54 | Injection site pruritus | FAERS: 3 | US FAERS | |
| 55 | Intentional product misuse | FAERS: 3 | US FAERS | |
| 56 | Joint swelling | FAERS: 3 | US FAERS | |
| 57 | Lymphoma | FAERS: 3 | US FAERS | |
| 58 | Mental impairment | FAERS: 3 | US FAERS | |
| 59 | Nervousness | FAERS: 3 | US FAERS | |
| 60 | Night sweats | FAERS: 3 | US FAERS | |
| 61 | Orchitis | FAERS: 3 | US FAERS | |
| 62 | Pain | FAERS: 3 | US FAERS | |
| 63 | Personality Change | FAERS: 3 | US FAERS | |
| 64 | Product use issue | FAERS: 3 | US FAERS | |
| 65 | Suspected counterfeit product | FAERS: 3 | US FAERS | |
| 66 | Urine flow decreased | FAERS: 3 | US FAERS | |
| 67 | jaundice | FAERS: 3 | US FAERS | |
| 68 | Abdominal Pain | FAERS: 2 | US FAERS | |
| 69 | Abdominal discomfort | FAERS: 2 | US FAERS | |
| 70 | Anaphylactic shock | FAERS: 2 | US FAERS | |
| 71 | Anger | FAERS: 2 | US FAERS | |
| 72 | Back Pain | FAERS: 2 | US FAERS | |
| 73 | Bipolar Disorder | FAERS: 2 | US FAERS | |
| 74 | Cellulitis | FAERS: 2 | US FAERS | |
| 75 | Crying | FAERS: 2 | US FAERS | |
| 76 | Drug level below therapeutic | FAERS: 2 | US FAERS | |
| 77 | Drug monitoring procedure not performed | FAERS: 2 | US FAERS | |
| 78 | Drug prescribing error | FAERS: 2 | US FAERS | |
| 79 | Dyspepsia | FAERS: 2 | US FAERS | |
| 80 | Dysphonia | FAERS: 2 | US FAERS | |
| 81 | Emotional disorder | FAERS: 2 | US FAERS | |
| 82 | Emotional distress | FAERS: 2 | US FAERS | |
| 83 | Epididymitis | FAERS: 2 | US FAERS | |
| 84 | Extraocular Muscle Paresis | FAERS: 2 | US FAERS | |
| 85 | General physical health deterioration | FAERS: 2 | US FAERS | |
| 86 | Head discomfort | FAERS: 2 | US FAERS | |
| 87 | Hypertrichosis | FAERS: 2 | US FAERS | |
| 88 | Impaired quality of life | FAERS: 2 | US FAERS | |
| 89 | Incorrect drug administration duration | FAERS: 2 | US FAERS | |
| 90 | Injection Site Reaction | FAERS: 2 | US FAERS | |
| 91 | Injection site cellulitis | FAERS: 2 | US FAERS | |
| 92 | Injection site discomfort | FAERS: 2 | US FAERS | |
| 93 | Injection site granuloma | FAERS: 2 | US FAERS | |
| 94 | Injection site mass | FAERS: 2 | US FAERS | |
| 95 | Injection site warmth | FAERS: 2 | US FAERS | |
| 96 | Lethargy | FAERS: 2 | US FAERS | |
| 97 | Lip swelling | FAERS: 2 | US FAERS | |
| 98 | Low density lipoprotein increased | FAERS: 2 | US FAERS | |
| 99 | Muscular Dystrophy | FAERS: 2 | US FAERS | |
| 100 | Musculoskeletal stiffness | FAERS: 2 | US FAERS | |
| 101 | Oropharyngeal discomfort | FAERS: 2 | US FAERS | |
| 102 | Oropharyngeal pain | FAERS: 2 | US FAERS | |
| 103 | Overdose | FAERS: 2 | US FAERS | |
| 104 | Polyneuropathy | FAERS: 2 | US FAERS | |
| 105 | Presyncope | FAERS: 2 | US FAERS | |
| 106 | Product dose omission | FAERS: 2 | US FAERS | |
| 107 | Product storage error | FAERS: 2 | US FAERS | |
| 108 | Product supply issue | FAERS: 2 | US FAERS | |
| 109 | Productive Cough | FAERS: 2 | US FAERS | |
| 110 | Pulmonary Embolism | FAERS: 2 | US FAERS | |
| 111 | Respiratory distress | FAERS: 2 | US FAERS | |
| 112 | Spontaneous penile erection | FAERS: 2 | US FAERS | |
| 113 | Therapy cessation | FAERS: 2 | US FAERS | |
| 114 | Thrombosis | FAERS: 2 | US FAERS | |
| 115 | Tremor | FAERS: 2 | US FAERS | |
| 116 | prostatitis | FAERS: 2 | US FAERS | |
| 117 | Adverse event | FAERS: 1 | US FAERS | |
| 118 | Angina Pectoris | FAERS: 1 | US FAERS | |
| 119 | Anhedonia | FAERS: 1 | US FAERS | |
| 120 | Anorectal discomfort | FAERS: 1 | US FAERS | |
| 121 | Aortic Aneurysm | FAERS: 1 | US FAERS | |
| 122 | Ascites | FAERS: 1 | US FAERS | |
| 123 | Aspermia | FAERS: 1 | US FAERS | |
| 124 | Asthma | FAERS: 1 | US FAERS | |
| 125 | Azoospermia | FAERS: 1 | US FAERS | |
| 126 | Bacterial prostatitis | FAERS: 1 | US FAERS | |
| 127 | Blood cholesterol increased | FAERS: 1 | US FAERS | |
| 128 | Blood count abnormal | FAERS: 1 | US FAERS | |
| 129 | Blood follicle stimulating hormone decreased | FAERS: 1 | US FAERS | |
| 130 | Blood glucose increased | FAERS: 1 | US FAERS | |
| 131 | Blood testosterone abnormal | FAERS: 1 | US FAERS | |
| 132 | Blood triglycerides abnormal | FAERS: 1 | US FAERS | |
| 133 | Bradycardia | FAERS: 1 | US FAERS | |
| 134 | Breast cancer stage III | FAERS: 1 | US FAERS | |
| 135 | Bronchitis | FAERS: 1 | US FAERS | |
| 136 | Cachexia | FAERS: 1 | US FAERS | |
| 137 | Cardiac Arrest | FAERS: 1 | US FAERS | |
| 138 | Cardiac discomfort | FAERS: 1 | US FAERS | |
| 139 | Cerebral ataxia | FAERS: 1 | US FAERS | |
| 140 | Cerebrovascular accident | FAERS: 1 Canada Vigilance: 1 | Canada Vigilance US FAERS | |
| 141 | Cervix carcinoma | FAERS: 1 | US FAERS | |
| 142 | Cheilitis | FAERS: 1 | US FAERS | |
| 143 | Chemical burns of eye | FAERS: 1 | US FAERS | |
| 144 | Choking | FAERS: 1 | US FAERS | |
| 145 | Cholecystitis | FAERS: 1 | US FAERS | |
| 146 | Cholelithiasis | FAERS: 1 | US FAERS | |
| 147 | Clostridium difficile infection | FAERS: 1 | US FAERS | |
| 148 | Contraindicated product administered | FAERS: 1 | US FAERS | |
| 149 | Cyanosis | FAERS: 1 | US FAERS | |
| 150 | Cyst | FAERS: 1 | US FAERS | |
| 151 | Dark circles under eyes | FAERS: 1 | US FAERS | |
| 152 | Deformity | FAERS: 1 | US FAERS | |
| 153 | Depressed Level of Consciousness | FAERS: 1 | US FAERS | |
| 154 | Depression suicidal | FAERS: 1 | US FAERS | |
| 155 | Discomfort | FAERS: 1 | US FAERS | |
| 156 | Drug effect delayed | FAERS: 1 | US FAERS | |
| 157 | Dysuria | FAERS: 1 | US FAERS | |
| 158 | Eczema | FAERS: 1 | US FAERS | |
| 159 | Embolism | FAERS: 1 | US FAERS | |
| 160 | Epilepsy | FAERS: 1 | US FAERS | |
| 161 | Erythema Multiforme | FAERS: 1 | US FAERS | |
| 162 | Exposure via direct contact | FAERS: 1 | US FAERS | |
| 163 | Eye pain | FAERS: 1 | US FAERS | |
| 164 | Fasciitis | FAERS: 1 | US FAERS | |
| 165 | Feeling jittery | FAERS: 1 | US FAERS | |
| 166 | Formication | FAERS: 1 | US FAERS | |
| 167 | Frustration tolerance decreased | FAERS: 1 | US FAERS | |
| 168 | Gastric Bypass | FAERS: 1 | US FAERS | |
| 169 | Glioma | FAERS: 1 | US FAERS | |
| 170 | Hemiparesis | FAERS: 1 | US FAERS | |
| 171 | Human chorionic gonadotropin increased | FAERS: 1 | US FAERS | |
| 172 | Hunger | FAERS: 1 | US FAERS | |
| 173 | Hypogonadism | FAERS: 1 | US FAERS | |
| 174 | Impatience | FAERS: 1 | US FAERS | |
| 175 | Incorrect dose administered | FAERS: 1 | US FAERS | |
| 176 | Incorrect product storage | FAERS: 1 | US FAERS | |
| 177 | Increased viscosity of upper respiratory secretion | FAERS: 1 | US FAERS | |
| 178 | Infection | FAERS: 1 | US FAERS | |
| 179 | Infertility | FAERS: 1 | US FAERS | |
| 180 | Inflammation | FAERS: 1 | US FAERS | |
| 181 | Influenza | FAERS: 1 | US FAERS | |
| 182 | Injection related reaction | FAERS: 1 | US FAERS | |
| 183 | Injection site abscess | FAERS: 1 | US FAERS | |
| 184 | Injection site cyst | FAERS: 1 | US FAERS | |
| 185 | Injection site deformation | FAERS: 1 | US FAERS | |
| 186 | Injection site infection | FAERS: 1 | US FAERS | |
| 187 | Injection site irritation | FAERS: 1 | US FAERS | |
| 188 | Intentional dose omission | FAERS: 1 | US FAERS | |
| 189 | Intentional self-injury | FAERS: 1 | US FAERS | |
| 190 | Laryngospasm | FAERS: 1 | US FAERS | |
| 191 | Libido disorder | FAERS: 1 | US FAERS | |
| 192 | Limb discomfort | FAERS: 1 | US FAERS | |
| 193 | Lymphadenopathy | FAERS: 1 | US FAERS | |
| 194 | Medication Error | FAERS: 1 Canada Vigilance: 1 | Canada Vigilance US FAERS | |
| 195 | Memory impairment | FAERS: 1 | US FAERS | |
| 196 | Metastasis | FAERS: 1 | US FAERS | |
| 197 | Monoplegia | FAERS: 1 | US FAERS | |
| 198 | Muscle hypertrophy | FAERS: 1 | US FAERS | |
| 199 | Muscle tightness | FAERS: 1 | US FAERS | |
| 200 | Musculoskeletal Pain | FAERS: 1 | US FAERS | |
| 201 | Musculoskeletal chest pain | FAERS: 1 | US FAERS | |
| 202 | Musculoskeletal discomfort | FAERS: 1 | US FAERS | |
| 203 | Myalgia | FAERS: 1 | US FAERS | |
| 204 | Myocardial Infarction | FAERS: 1 Canada Vigilance: 1 | Canada Vigilance US FAERS | |
| 205 | Nasopharyngitis | FAERS: 1 | US FAERS | |
| 206 | No adverse event | FAERS: 1 | US FAERS | |
| 207 | Occupational exposure to product | FAERS: 1 | US FAERS | |
| 208 | Oral pruritus | FAERS: 1 | US FAERS | |
| 209 | Pancreatitis | FAERS: 1 | US FAERS | |
| 210 | Pericardial effusion | FAERS: 1 | US FAERS | |
| 211 | Physical disability | FAERS: 1 | US FAERS | |
| 212 | Pneumonia | FAERS: 1 | US FAERS | |
| 213 | Polymyalgia Rheumatica | FAERS: 1 | US FAERS | |
| 214 | Poor quality drug administered | FAERS: 1 | US FAERS | |
| 215 | Portal Vein Thrombosis | FAERS: 1 | US FAERS | |
| 216 | Priapism | FAERS: 1 | US FAERS | |
| 217 | Procedural dizziness | FAERS: 1 | US FAERS | |
| 218 | Product administered at inappropriate site | FAERS: 1 | US FAERS | |
| 219 | Product availability issue | FAERS: 1 | US FAERS | |
| 220 | Product contamination | FAERS: 1 | US FAERS | |
| 221 | Product packaging issue | FAERS: 1 | US FAERS | |
| 222 | Product physical consistency issue | FAERS: 1 | US FAERS | |
| 223 | Product use in unapproved indication | FAERS: 1 | US FAERS | |
| 224 | Pulmonary Hypertension | FAERS: 1 | US FAERS | |
| 225 | Pulmonary congestion | FAERS: 1 | US FAERS | |
| 226 | Reaction to drug excipients | FAERS: 1 | US FAERS | |
| 227 | Respiratory arrest | FAERS: 1 | US FAERS | |
| 228 | Retching | FAERS: 1 | US FAERS | |
| 229 | Rhinalgia | FAERS: 1 | US FAERS | |
| 230 | Rhonchi | FAERS: 1 | US FAERS | |
| 231 | Rotator cuff syndrome | FAERS: 1 | US FAERS | |
| 232 | Sciatica | FAERS: 1 | US FAERS | |
| 233 | Sense of oppression | FAERS: 1 | US FAERS | |
| 234 | Septic arthritis staphylococcal | FAERS: 1 | US FAERS | |
| 235 | Sinusitis | FAERS: 1 | US FAERS | |
| 236 | Skin reaction | FAERS: 1 | US FAERS | |
| 237 | Sperm concentration abnormal | FAERS: 1 | US FAERS | |
| 238 | Spermatozoa progressive motility abnormal | FAERS: 1 | US FAERS | |
| 239 | Stress | FAERS: 1 | US FAERS | |
| 240 | Subcutaneous Abscess | FAERS: 1 | US FAERS | |
| 241 | Swelling | FAERS: 1 | US FAERS | |
| 242 | Tachycardia | FAERS: 1 | US FAERS | |
| 243 | Tension | FAERS: 1 | US FAERS | |
| 244 | Therapeutic response unexpected | FAERS: 1 | US FAERS | |
| 245 | Throat clearing | FAERS: 1 | US FAERS | |
| 246 | Tinnitus | FAERS: 1 | US FAERS | |
| 247 | Tongue pruritus | FAERS: 1 | US FAERS | |
| 248 | Transaminases increased | FAERS: 1 | US FAERS | |
| 249 | Urinary Incontinence | FAERS: 1 | US FAERS | |
| 250 | Urinary tract infection | FAERS: 1 | US FAERS | |
| 251 | Urinary tract obstruction | FAERS: 1 | US FAERS | |
| 252 | Urticaria | FAERS: 1 | US FAERS | |
| 253 | Vascular occlusion | FAERS: 1 | US FAERS | |
| 254 | Vertigo | FAERS: 1 | US FAERS | |
| 255 | Vomiting | FAERS: 1 | US FAERS | |
| 256 | Wrong technique in drug usage process | FAERS: 1 | US FAERS | |
| 257 | Ear congestion | Canada Vigilance: 1 | Canada Vigilance | |
| 258 | Product physical issue | Canada Vigilance: 1 | Canada Vigilance | |
| 259 | Product substitution issue | Canada Vigilance: 1 | Canada Vigilance | |
| 260 | Suprapubic pain | Canada Vigilance: 2 | Canada Vigilance |
Powered by :
Page last updated at 2020-05-25 10:01:57 (Asia/Shanghai) | You are visitor No. 120239
Copyright © 2019-2020 Laboratory of Molecular Modeling and Design, Shanghai Key Laboratory of New Drug Design, School of Pharmacy, East China University of Science and Technology. All rights reserved.